期刊文献+

反相高效液相色谱法测定维格列汀 被引量:3

Determination of Vildagliptin by RP-HPLC
原文传递
导出
摘要 建立反相高效液相色谱法测定维格列汀的含量。采用Venusil MP C18色谱柱(250mm×4.6mm,5μm),流动相为磷酸盐缓冲溶液(称取20mmol·L^(-1)磷酸二氢钾,用85%浓磷酸调至pH3.0)-乙腈(88:12,V/V),检测波长为210nm,流速为1.0mL·min^(-1),柱温为25℃。维格列汀在5—500μg·mL^(-1)范围内与峰面积呈良好的线性关系(r=0.9999),维格列汀的平均回收率为102.0%,RSD为2.65%。方法准确、简便,适用于维格列汀的定量分析。 The content of vildagliptin was determined by RP-HPLC.The separation conditions were as follows:column was Venusil MP C18(250mm×4.6mm,5μm),mobile phase was phosphate buffer(pH of the weighed 20mmol·L^-1 monopotassium phosphate was adjusted to 3.0 by 85% phosphoric acid)-acetonitrile(88:12,V/V),detection wavelength was 210nm,flow rate was 1.0 mL·min^-1 and the column temperature was 25℃.The vildagliptin had the good linear relationship with peak area in the rang of 5-500μg·mL-1(r=0.9999),and the average recovery was 102.0% with RSD of 2.65%.This method is reliable,accurate and suitable,and can be applied to quantitative analysis of vildagliptin.
出处 《光谱实验室》 CAS CSCD 2012年第4期2555-2558,共4页 Chinese Journal of Spectroscopy Laboratory
关键词 维格列汀 反相高效液相色谱法 含量 Vildagliptin RP-HPLC Content
  • 相关文献

参考文献2

二级参考文献29

  • 1夏玲红.治疗糖尿病的新药西他列汀[J].中国新药杂志,2007,16(12):979-981. 被引量:26
  • 2PRATLEY RE, SALSALI A, MATFIN G. Inhibition of dipeptidyl peptidase-4 with vildagliptin : a potential new treatment for type 2 diabetes[ J]. Br J Diabetes Vasc Dis,2006,6(4) : 150 - 156. 被引量:1
  • 3VILLHAUER EB, BRINKMAN JA, NADERI GB, et al. 1-[ [ ( 3- hydroxy-1 - adamantyl ) amino ] acetyl ] -2-cyano-( S ) - pyrrolidine : a potent, selective, and orally bioavailable dipeptidyl peptidase Ⅳ inhibitor with antihyperglycemic properties[ J ]. J Med Chem, 2003,46 ( 13 ) :2774 - 2789. 被引量:1
  • 4MARGUET D, BAGGIO L,KOBAYASHI,et al. Enhanced insulin secretion and inproved glucose tolerance in mice lacking CD26 [ J ]. Proc Natl Acad Sci USA ,2000,97 ( 12 ) :6874 - 6879. 被引量:1
  • 5NAGAKUBA T, YASUDA N,YAMAZAKI K,et al. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptldyl peptidase Ⅳ- deficient Fischer rats [ J ]. Biochem Biophys Res Commun,2001,284(2 ) :501 - 506. 被引量:1
  • 6HE Y,BALCH A, CAMPESTRINI J, et al. Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with type 2 diabetes [ J ]. Clin Pharmacol Ther,2005,77 ( 2 ) :56. 被引量:1
  • 7HE YL,SABO R,CAMPESTRINI J ,et al. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase Ⅳ ( DDP-4 ) inhibitor vildagliptin [ J ]. Eur J. Clin Pharm,2007, 63(7) :677 -686. 被引量:1
  • 8PRATLEY RE, JAUFFRET-KAMEL S, GALBREATH E,et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes [ J ]. Horm Metab Res ,2006,38 ( 6 ) :423 - 428. 被引量:1
  • 9RISTIC S, BYIERS S, FOLEY J,et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin ( LAF237 ) dose response [ J ]. Diabetes Obes Metab,2005,7 ( 6 ) : 692 - 698. 被引量:1
  • 10BOSI E,CAMISASCA RP,COLLOBER C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin [ J ]. Diabetes Care, 2007,30(4) :890 - 895. 被引量:1

共引文献33

同被引文献10

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部